Invitrogen Corporation (IVGN) Launches Biomarker Tool for Pre-Clinical Research into Kidney Function
7/30/2009 9:06:36 AM
CARLSBAD, Calif.--(BUSINESS WIRE)--Invitrogen, part of Life Technologies Corporation (NASDAQ:LIFE), today announced the global availability of a new biomarker tool for use in pre-clinical research into kidney function. The PlexMark™ 3 Renal Biomarker Panel Assay is a non-invasive and cost-effective research tool for performing kidney function post-transplantation studies rapidly and easily. The introduction of this research tool is expected to assist in the development of studies which may lead to more effective methods used to monitor kidney health in transplant research.